Kingsberg S A
Reproductive Biology & Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Int J Impot Res. 2005 Sep-Oct;17(5):465-6. doi: 10.1038/sj.ijir.3901375.
Has the FDA discriminated against female sexual dysfunction by not endorsing Procter & Gamble's (P&G) Intrinsa? Has the pendulum swung so far to the right that drugs for sexual medicine receive undue scrutiny? Why is testosterone replacement therapy available for men, but not for women? How should the pharmaceutical industry proceed with future studies? How should clinicians guide their patients? In this third and final perspective regarding Intrinsa, Sheryl Kingsberg, PhD, an expert on female sexual dysfunction and one of the lead investigators of the Intrinsa clinical trials, addresses these questions. This is a highly charged issue that appears to be on the agenda for the foreseeable future.
美国食品药品监督管理局（FDA）不批准宝洁公司（P&G）的依思翠（Intrinsa），这是否构成了对女性性功能障碍的歧视？形势是否已经过度右倾，以至于性医学药物受到了过度审查？为什么睾酮替代疗法适用于男性，却不适用于女性？制药行业未来的研究应如何开展？临床医生应如何指导他们的患者？在关于依思翠的这第三个也是最后一个观点中，女性性功能障碍专家、依思翠临床试验的主要研究者之一谢丽尔·金斯伯格博士回答了这些问题。这是一个高度敏感的问题，在可预见的未来似乎都将被提上议程。
